EI

249.3

-1.73%↓

SHL.DE

45.61

-1.04%↓

ARGX

581.4

-0.34%↓

PHIA

22.58

-1.1%↓

SRT3

177.15

-0.67%↓

EI

249.3

-1.73%↓

SHL.DE

45.61

-1.04%↓

ARGX

581.4

-0.34%↓

PHIA

22.58

-1.1%↓

SRT3

177.15

-0.67%↓

EI

249.3

-1.73%↓

SHL.DE

45.61

-1.04%↓

ARGX

581.4

-0.34%↓

PHIA

22.58

-1.1%↓

SRT3

177.15

-0.67%↓

EI

249.3

-1.73%↓

SHL.DE

45.61

-1.04%↓

ARGX

581.4

-0.34%↓

PHIA

22.58

-1.1%↓

SRT3

177.15

-0.67%↓

EI

249.3

-1.73%↓

SHL.DE

45.61

-1.04%↓

ARGX

581.4

-0.34%↓

PHIA

22.58

-1.1%↓

SRT3

177.15

-0.67%↓

Search

Sanofi SA

Atvērts

SektorsVeselības aprūpe

80.1 -2.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

79.92

Max

82.45

Galvenie mērījumi

By Trading Economics

Ienākumi

3.9B

5.8B

Pārdošana

11B

21B

P/E

Sektora vidējais

15.922

34.393

EPS

1.59

Dividenžu ienesīgums

4.88

Peļņas marža

27.234

Darbinieki

82,878

EBITDA

2.2B

2.8B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+31.89% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.88%

2.54%

Nākamie ieņēmumi

2025. g. 24. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-4.1B

100B

Iepriekšējā atvēršanas cena

82.74

Iepriekšējā slēgšanas cena

80.1

Ziņu noskaņojums

By Acuity

37%

63%

123 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Sanofi SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 10:06 UTC

Galvenie tirgus virzītāji

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

2025. g. 31. jūl. 06:00 UTC

Peļņas

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

2025. g. 30. jūl. 10:20 UTC

Peļņas

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

2025. g. 30. jūl. 05:31 UTC

Peļņas

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

2025. g. 6. aug. 05:02 UTC

Iegādes, apvienošanās, pārņemšana

Sanofi Completes the Acquisition of Vigil Neuroscience

2025. g. 6. aug. 05:00 UTC

Iegādes, apvienošanās, pārņemšana

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

2025. g. 1. aug. 13:16 UTC

Peļņas

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025. g. 1. aug. 12:40 UTC

Peļņas

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025. g. 31. jūl. 08:15 UTC

Tirgus saruna
Peļņas

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

2025. g. 31. jūl. 05:56 UTC

Tirgus saruna
Peļņas

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Business Operating Profit EUR2.46B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Adj EPS EUR1.59

2025. g. 31. jūl. 05:30 UTC

Peļņas

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Net Pft EUR3.94B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi 2Q Sales EUR9.99B

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Backs 2025 EPS Adj View

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Narrows 2025 Sales View

2025. g. 31. jūl. 05:30 UTC

Peļņas

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

2025. g. 30. jūl. 07:48 UTC

Tirgus saruna
Peļņas

Santander Results Get Lukewarm Reaction -- Market Talk

2025. g. 30. jūl. 06:41 UTC

Tirgus saruna
Peļņas

Santander's Strategic Investments in Focus -- Market Talk

2025. g. 30. jūl. 04:52 UTC

Peļņas

Santander End-2Q CET1 Ratio 13%

Salīdzinājums

Cenas izmaiņa

Sanofi SA Prognoze

Cenas mērķis

By TipRanks

31.89% augšup

Prognoze 12 mēnešiem

Vidējais 108.192 EUR  31.89%

Augstākais 123.956 EUR

Zemākais 89.968 EUR

Pamatojoties uz 14 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Sanofi SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

14 ratings

9

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

91.3 / 96.1Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

123 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.